There are 3 monoclonal antibodies that have been given EUA over the years:
- bamlanivimab/etesezumab (Eli Lilly's product)
- casirivimab/indevimab (REGEN-COV, Regeneron's product)
- sotrovimab (GSK's product)
Against Omicron, Eli Lilly's and Regeneron's products lost effectiveness by a factor of ~1,000. They're very expensive and they don't work well vs. Omicron. Only sotrovimab (GSK's product) retains effectiveness. Given that the other variants are no longer circulating and there's no place in therapy for these drugs, FDA stopped the EUAs. Experiment's over. Sotrovimab is the only one still available because it still works. That's the logic.
Edit: after reading through ~100 replies worth of emotional reaction and conspiracy theory, I'd respectfully ask the OP to edit the original post to include this explanation. This isn't nefarious. The other 2 options simply don't work anymore, and we shouldn't have FDA approving drugs that don't work.
Clarification:
There are 3 monoclonal antibodies that have been given EUA over the years:
- bamlanivimab/etesezumab (Eli Lilly's product)
- casirivimab (REGEN-COV, Regeneron's product)
- sotrovimab (GSK's product)
Against Omicron, Eli Lilly's and Regeneron's products lost effectiveness by a factor of ~1,000. They're very expensive and they don't work well vs. Omicron. Only sotrovimab (GSK's product) retains effectiveness. Given that the other variants are no longer circulating and there's no place in therapy for these drugs, FDA stopped the EUAs. Experiment's over. Sotrovimab is the only one still available because it still works. That's the logic.